SynthesisVeterinary medicine and science2026
Receptor-Targeted Antiemetic Strategies in Cats: A Systematic Review and Intervention-Specific Meta-Analysis.
Synthesis in Veterinary medicine and science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundEmesis is a common adverse effect in cats receiving alpha-2 adrenergic agonists and opioids and may compromise perioperative welfare and safety. Comparative evidence for feline antiemetic protocols remains limited by heterogeneity in triggers, timing and outcomes.
objectivesTo evaluate receptor-targeted antiemetic strategies in cats and quantitatively synthesise controlled event-level evidence for emesis incidence where appropriate.
methodsThis systematic review followed PRISMA 2020 principles. Controlled feline studies assessing maropitant, ondansetron or metoclopramide for prevention or treatment of emesis were eligible. The primary meta-analysis was restricted to maropitant versus control. Risk ratios (RRs) were pooled on the log scale using a random-effects model with Paule-Mandel estimation and Hartung-Knapp adjustment.
resultsFive controlled studies contributed to the primary maropitant analysis. Emesis occurred in 11/141 cats given maropitant and 70/152 controls. Maropitant reduced emesis risk (RR = 0.20, 95% confidence interval [CI]: 0.08-0.55), with low-to-moderate heterogeneity (I
conclusionsMaropitant currently has the most consistent controlled evidence for reducing emesis incidence in cats under perioperative or induced-emesis conditions. Further adequately powered, blinded and randomised trials using standardised vomiting, retching and nausea outcomes are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.